October Pharma results, Fiscal year 2023
Net profit, assets, equity and cash flow for Fiscal year 2023, against the same period a year earlier, from the published financial statements.
Net profit51.39 millionEGP · −60.7% vs the same period a year earlier
Total assets1.14 billionEGP · +19.8% vs the same period a year earlier
Shareholders' equity590 millionEGP · +38.5% vs the same period a year earlier
Operating cash flow153 millionEGP · +265.6% vs the same period a year earlier
In short
- October Pharma's net profit for Fiscal year 2023 was about 51.39 million EGP, down −60.7% from 131 million EGP in Fiscal year 2022.
- Total assets at the end of Fiscal year 2023 were about 1.14 billion EGP, and shareholders' equity about 590 million EGP.
- Operating cash flow for Fiscal year 2023 was positive at 153 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2022Change
Net profit51.39 million131 million−60.7%
Gross profit511 million370 million+38.1%
Total assets1.14 billion950 million+19.8%
Total liabilities549 million524 million+4.6%
Shareholders' equity590 million426 million+38.5%
Total liabilities and equity1.14 billion950 million+19.8%
Operating cash flow153 million-92.33 million+265.6%
Investing cash flow-2.1 million-94.31 million+97.8%
Financing cash flow-79.09 million177 million−144.7%
Net change in cash38.38 million-9.81 million+491.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy